SCHEMBL19534278

SCHEMBL19534278

O=C1NC2(CCNCC2)C(=O)N1c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.53
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
HSD17B10 Q99714 1/20 0.46
TSHR P16473 2/20 0.46
USP2 O75604 2/20 0.45
CYP2D6 P10635 2/20 0.45
IDO1 P14902 1/20 0.43
TDO2 P48775 1/20 0.43
EGLN1 Q9GZT9 2/20 0.42
EGLN3 Q9H6Z9 2/20 0.42
ALDH1A1 P00352 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C19 P33261 1/20 0.41
GAA P10253 1/20 0.41
RECQL P46063 1/20 0.41
AR P10275 2/20 0.40
OPRM1 P35372 1/20 0.40
HTR3E A5X5Y0 1/20 0.40
HTR3B O95264 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21150857 0.90 POLB (0.46) POLBNPC1RAB9AHSD17B10TSHR
SCHEMBL13879542 0.86 POLB (0.65) POLBNPC1RAB9AIDO1TDO2
SCHEMBL21150846 0.83 AR (0.57) POLBNPC1RAB9AHSD17B10TSHR
SCHEMBL21151326 0.83 HTT (0.50) POLBCYP2D6CYP3A4CYP2C19GAA
SCHEMBL21151171 0.82 AR (0.61) POLBNPC1RAB9AHSD17B10IDO1
SCHEMBL21151348 0.81 POLB (0.51) POLBNPC1RAB9ATSHRUSP2
SCHEMBL19534073 0.80 POLB (0.50) POLBNPC1RAB9AIDO1TDO2
SCHEMBL19534078 0.80 POLB (0.54) POLBNPC1RAB9AIDO1TDO2
SCHEMBL23288931 0.80 POLB (0.50) POLBNPC1RAB9AEGLN1EGLN3
Hydrochloric Acid SCHEMBL21753212 0.80 POLB (0.50) POLBNPC1RAB9ATSHRUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11572370-B2 CD16A binding agents and uses thereof BIOHAVEN THERAPEUTICS LTD. (US) 2023-02-07 US disclosed
EP-3448522-B1 NOVEL SUBSTITUTED IMIDAZOPYRIDINE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN-2,3-DIOXYGENASE IOMET PHARMA LTD (GB) 2021-01-20 EP disclosed
WO-2019136442-A1 CD16A BINDING AGENTS AND USES THEREOF KLEO PHARMACEUTICALS, INC. (US) 2019-07-11 WO disclosed
WO-2017189386-A1 NOVEL SUBSTITUTED IMIDAZOPYRIDINE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN-2,3-DIOXYGENASE IOMET PHARMA LTD. (GB) 2017-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11572370-B2 CD16A binding agents and uses thereof FCGR1A, FCGR2A, FCGR3B POLB 4058/4885NPC1 1745/4885RAB9A 2444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.